AMR Stakeholder Profile
Focus area/active in: Human Health | Therapeutics
Company/Organisation type: SME
Juvabis is a clinical-stage Swiss biopharmaceutical start-up that addresses the global challenge of life-threatening bacterial infections by designing and developing next-generation aminoglycoside-antibiotics. Juvabis aims to treat antibiotic-resistant infections with aminoglycoside-therapies of unprecedented safety and efficacy. Juvabis’ best-in-class clinical-candidate apramycin is currently in Phase 1 first-in-human trials, being developed in partnership with the Innovative Medicines Initiative.
Would you like to meet Juvabis virtually during the AMR Conference week?
Get in touch!
Head of Business Development
Please fill out the form below to get in touch with us.